252 related articles for article (PubMed ID: 20691606)
1. Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis.
Tsai AL; Burke CT; Kennedy AS; Moore DT; Mauro MA; Dixon RD; Stavas JM; Bernard SA; Khandani AH; O'Neil BH
J Vasc Interv Radiol; 2010 Sep; 21(9):1377-84. PubMed ID: 20691606
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres.
Biederman DM; Titano JJ; Tabori NE; Pierobon ES; Alshebeeb K; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Nowakowski FS; Kim E
J Vasc Interv Radiol; 2016 Jun; 27(6):812-821.e2. PubMed ID: 27062356
[TBL] [Abstract][Full Text] [Related]
3. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis.
Iñarrairaegui M; Thurston KG; Bilbao JI; D'Avola D; Rodriguez M; Arbizu J; Martinez-Cuesta A; Sangro B
J Vasc Interv Radiol; 2010 Aug; 21(8):1205-12. PubMed ID: 20598574
[TBL] [Abstract][Full Text] [Related]
4. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
[TBL] [Abstract][Full Text] [Related]
5. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.
Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C
Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis.
Kulik LM; Carr BI; Mulcahy MF; Lewandowski RJ; Atassi B; Ryu RK; Sato KT; Benson A; Nemcek AA; Gates VL; Abecassis M; Omary RA; Salem R
Hepatology; 2008 Jan; 47(1):71-81. PubMed ID: 18027884
[TBL] [Abstract][Full Text] [Related]
7. Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: The impact of portal vein thrombosis on survival.
Somma F; Stoia V; Serra N; D'Angelo R; Gatta G; Fiore F
PLoS One; 2019; 14(5):e0216935. PubMed ID: 31141552
[TBL] [Abstract][Full Text] [Related]
8. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis.
Kokabi N; Camacho JC; Xing M; El-Rayes BF; Spivey JR; Knechtle SJ; Kim HS
Cancer; 2015 Jul; 121(13):2164-74. PubMed ID: 25847227
[TBL] [Abstract][Full Text] [Related]
9. Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma.
Allimant C; Kafrouni M; Delicque J; Ilonca D; Cassinotto C; Assenat E; Ursic-Bedoya J; Pageaux GP; Mariano-Goulart D; Aho S; Guiu B
J Vasc Interv Radiol; 2018 Dec; 29(12):1662-1670.e4. PubMed ID: 30217745
[TBL] [Abstract][Full Text] [Related]
10.
Abouchaleh N; Gabr A; Ali R; Al Asadi A; Mora RA; Kallini JR; Mouli S; Riaz A; Lewandowski RJ; Salem R
J Nucl Med; 2018 Jul; 59(7):1042-1048. PubMed ID: 29217739
[TBL] [Abstract][Full Text] [Related]
11. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.
Garin E; Rolland Y; Edeline J; Icard N; Lenoir L; Laffont S; Mesbah H; Breton M; Sulpice L; Boudjema K; Rohou T; Raoul JL; Clement B; Boucher E
J Nucl Med; 2015 Mar; 56(3):339-46. PubMed ID: 25678490
[TBL] [Abstract][Full Text] [Related]
12. Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis.
Salem R; Lewandowski R; Roberts C; Goin J; Thurston K; Abouljoud M; Courtney A
J Vasc Interv Radiol; 2004 Apr; 15(4):335-45. PubMed ID: 15064336
[TBL] [Abstract][Full Text] [Related]
13. Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma.
Johnson GE; Monsky WL; Valji K; Hippe DS; Padia SA
J Vasc Interv Radiol; 2016 Aug; 27(8):1123-9. PubMed ID: 27321889
[TBL] [Abstract][Full Text] [Related]
14. Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization.
Xing M; Kokabi N; Camacho JC; Kim HS
BMC Cancer; 2018 Jan; 18(1):75. PubMed ID: 29329568
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of radioembolization according to tumor morphology and portal vein thrombosis in intermediate-advanced hepatocellular carcinoma.
Golfieri R; Mosconi C; Cappelli A; Giampalma E; Galaverni MC; Pettinato C; Renzulli M; Monari F; Angelelli B; Pini P; Terzi E; Ascanio S; Garzillo G; Piscaglia F; Bolondi L; Trevisani F
Future Oncol; 2015; 11(23):3133-42. PubMed ID: 26467398
[TBL] [Abstract][Full Text] [Related]
16. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity.
Padia SA; Kwan SW; Roudsari B; Monsky WL; Coveler A; Harris WP
J Vasc Interv Radiol; 2014 Jul; 25(7):1067-73. PubMed ID: 24837982
[TBL] [Abstract][Full Text] [Related]
17. Ablative Transarterial Radioembolization Improves Survival in Patients with HCC and Portal Vein Tumor Thrombus.
Cardarelli-Leite L; Chung J; Klass D; Marquez V; Chou F; Ho S; Walton H; Lim H; Tae Wan Kim P; Hadjivassiliou A; Liu DM
Cardiovasc Intervent Radiol; 2020 Mar; 43(3):411-422. PubMed ID: 31909439
[TBL] [Abstract][Full Text] [Related]
18. Same-Day Yttrium-90 Radioembolization: Feasibility with Resin Microspheres.
Li MD; Chu KF; DePietro A; Wu V; Wehrenberg-Klee E; Zurkiya O; Liu RW; Ganguli S
J Vasc Interv Radiol; 2019 Mar; 30(3):314-319. PubMed ID: 30819470
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
20. Yttrium-90 Glass-Based Microsphere Radioembolization in the Treatment of Hepatocellular Carcinoma Secondary to the Hepatitis B Virus: Safety, Efficacy, and Survival.
Biederman DM; Titano JJ; Lee KM; Pierobon ES; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Tabori NE; Nowakowski FS; Kim E
J Vasc Interv Radiol; 2015 Nov; 26(11):1630-8. PubMed ID: 26321014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
